NI
SPRY icon

Nextech Invest’s ARS Pharmaceuticals SPRY Stock Holding History

Nextech Invest’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-610,703
Closed -$4.9M – 17
2026
Q1 		$4.9M Sell
610,703
-50,000
-8% -$479K 0.35% 17
2025
Q4 		$7.7M Hold
660,703
– – 0.74% 13
2025
Q3 		$6.64M Sell
660,703
-81,026
-11% -$1.16M 1.01% 12
2025
Q2 		$12.9M Sell
741,729
-195,000
-21% -$2.81M 2.45% 8
2025
Q1 		$11.8M Hold
936,729
– – 2.74% 5
2024
Q4 		$9.88M Sell
936,729
-176,300
-16% -$2.47M 1.6% 12
2024
Q3 		$16.1M Sell
1,113,029
-797,000
-42% -$9.48M 2.27% 11
2024
Q2 		$16.3M Hold
1,910,029
– – 2.73% 11
2024
Q1 		$19.5M Hold
1,910,029
– – 3.09% 10
2023
Q4 		$10.5M Hold
1,910,029
– – 1.95% 11
2023
Q3 		$7.22M Hold
1,910,029
– – 2.19% 8
2023
Q2 		$12.8M Hold
1,910,029
– – 4.35% 6
2023
Q1 		$12.4M Hold
1,910,029
– – 5.19% 6
2022
Q4 		$16.3M Hold
1,910,029
– – 6.48% 4
2022
Q3 		$10.1M Hold
1,910,029
– – 3.26% 11
2022
Q2 		$8.1M Hold
1,910,029
– – 2.73% 10
2022
Q1 		$6.7M Hold
1,910,029
– – 1.91% 14
2021
Q4 		$12.7M Buy
+1,910,029
New +$15.5M 3.35% 9

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Nextech Invest's SPRY Position: Q2 2026 in Review

Nextech Invest sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 610,703 shares — an estimated $4.9M sold.

Nextech Invest first reported a position in SPRY in Q4 2021 and held it in 18 quarters. The position peaked at $19.5M in Q1 2024. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Nextech Invest reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Nextech Invest sold 610,703 ARS Pharmaceuticals shares in Q2 2026, an estimated $4.9M.
  • Nextech Invest first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 18 quarters.
  • Nextech Invest's ARS Pharmaceuticals position peaked at $19.5M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Nextech Invest's 13F filing for Q2 2026, filed 14 Aug 2026.